One of the most high profile -- and controversial -- papers in the adult stem cell field has been called into further question this month after a university investigation raised concerns about the ...
Currently, most therapies for allergic diseases require lifelong treatment. Allergic reactions, characterized by ongoing (type 2) inflammation in response to chronic antigen exposure, underlie many ...
CLEVELAND & LEXINGTON, Ky.--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results